Development and Validation of a Tool for Patient-reported Assessment of Cancer-related Financial Toxicity in Italy

Summary

The aim of this study is to develop and validate a patient-reported-outcome instrument (PROFTC-I: Patient Reported Outcome Financial Toxicity in Cancer - Italy) able to describe and measure financial problems of Italian patients receiving cancer treatment.

Conditions

• Cancer

Sponsors & Collaborators

• National Cancer Institute, Naples

  lead OTHER

Principal Investigators

• Francesco Perrone · Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale

• Jane Bryce · Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale

• Ciro Gallo · University of Campania Luigi Vanvitelli

• Silvia Riva · St. Mary University, Twickenham, London, GB

• Fabio Efficace · Northwestern University, Feinberg School of Medicine, GIMEMA,EORTC Quality of Life Group - Rappresentante GIMEMA

• Francesco De Lorenzo · AIMAC and European Cancer Patient Coalition

• Elisabetta Iannelli · Segretario Generale FAVO

• Laura Del Campo · FAVO

• Francesca Traclò · AIMAC

• Massimo Di Maio · AO Ordine Mauriziano

• Luciano Frontini · Federation of Italian Cooperative Oncology Groups

• Vincenzo Montesarchio · Oncologia, Azienda dei Colli, Napoli - CIPOMO

• Lara Gitto · Centro per gli Studi Economici e Internazionali - Economic Evaluation & Health Technology Assessment (CEIS EEHTA), Università di Roma "Tor Vergata"

• Claudio Jommi · Dipartimento di Scienze del Farmaco, Università del Piemonte Orientale; Osservatorio Farmaci, Cergas, SDA Bocconi

• Concetta Maria Vaccaro · Welfare e Salute CENSIS (Centro Studi Investimenti Sociali), Roma

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-03-01

Primary Completion

2024-02-01

Completion

2024-07-01

Countries

• Italy

Study Locations